Inhibrx Biosciences, Inc. stays a Strong Buy with Q2 2026 ozekibart BLA catalyst, 2026 PFS data, and Ewing sarcoma updates.

Dublin, July 29, 2025 (GLOBE NEWSWIRE) -- The "Chondrosarcoma Market - A Global and Regional Analysis: Focus on Type, Treatment Type, and Region - Analysis and Forecast, 2025-2035" report has been ...

Mumbai: Dr Arsheed Hussain Hakeem, Senior Consultant – Surgical Oncology, Apollo Cancer Centre, Hyderabad speaking to Prabhat Prakash of ETHealthworld discussed the rarity of mesenchymal ...

Chondrosarcoma represents a heterogeneous group of primary malignant tumours arising from cartilaginous tissues. These tumours vary widely in clinical behaviour, ranging from slow-growing, locally ...

Chondrosarcoma is a malignant tumour characterised by the generation of a cartilaginous matrix by neoplastic cells. When occurring in the craniofacial region, particularly within the temporomandibular ...

Please provide your email address to receive an email when new articles are posted on . The patient is a 57-year-old, right-handed, retired postal worker. He presented with a chief complaint of ...

Osteosarcoma (OS), chondrosarcoma, and chordoma are characterized by multiple challenges to the investigator, clinician, and patient. One consequence of their rarity among sarcomas, as well as their ...

SAN DIEGO, Oct. 22, 2025 /PRNewswire/ -- Inhibrx Biosciences, Inc. (Nasdaq: INBX) ("Inhibrx" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapeutics for ...

— Company Granted U.S. Orphan Drug Designation for IPI-926 for the Treatment of Chondrosarcoma — — Rationale for Developing IPI-926 in Chondrosarcoma to be Highlighted During a Hedgehog Pathway ...

Doctors gave me terrifying news so I took matters into my own hands. I was watching The Woman With No Face, a documentary about young mum Tambu Makinzi fighting for her life. She had a 2kg tumour, ...

Osteosarcoma (OS), chondrosarcoma, and chordoma are characterized by multiple challenges to the investigator, clinician, and patient. One consequence of their rarity among sarcomas, as well as their ...